WITHDRAWN: B7H3 negatively mediates osteogenic differentiation of mesenchymal stem cells by suppressing AKT1 activation

Kaida Huang,Hongli Mao,Cailin Liu
DOI: https://doi.org/10.1016/j.bbrc.2021.08.045
IF: 3.1
2021-08-01
Biochemical and Biophysical Research Communications
Abstract:Osteoporosis is a prevalent metabolic bone disease with low bone mass and degenerative disorders of bone tissues. Abnormal osteogenic differentiation of bone marrow mesenchymal stem cells (MSCs) is involved in osteoporosis progression. Nevertheless, the underlying mechanisms for such event are still largely unknown. B7 family member B7H3 plays a critical role in regulating diverse cellular processes, but little is known about its effects on osteoporosis. In our present study, we found that B7H3 expression was down-regulated upon osteogenic induction, and remarkably decreased B7H3 expression was detected in bone marrow derived MSCs from ovariectomized (OVX) mice. Notably, we found that B7H3 conditional knockout (B7H3cKO) in bone marrow MSCs considerably strengthened bone mass in OVX-challenged mice. Loss-of-function experiments indicated that B7H3 ablation remarkably improved the osteogenic differentiation of MSCs both in vitro and in vivo, accompanied by restrained inflammatory response and NF-κB activation. Mechanistically, a direct association between B7H3 and AKT1 was detected. B7H3 deletion strongly up-regulated AKT1 activation in MSCs during osteogenic induction in vitro and in vivo. Further studies suggested that B7H3 knockdown-improved osteogenic differentiation was almost abolished by the blockage of AKT1 activation, demonstrating that B7H3-mediated osteogenic differentiation was largely AKT1-dependent. Together, our results concluded that B7H3 is a critical modulator for osteogenesis of MSCs, and can be a promising therapeutic target for osteoporosis treatment.
biochemistry & molecular biology,biophysics
What problem does this paper attempt to address?